HOME >> BIOLOGY >> NEWS
JCI Table of Contents, May 1, 2003

08
Fax: 312-702-2281
E-mail: ama@medicine.bsd.uchicago.edu

View the PDF of this commentary at: https://www.the-jci.org/press/18545.pdf


PTG gene deletion causes impaired glycogen synthesis and developmental insulin resistance

AUTHOR CONTACT:
Alan R. Saltiel
The University of Michigan Medical Center, Ann Arbor, Michigan, USA.
Phone : 734-615-9787
Fax : 734-936-2888
E-mail: saltiel@umich.edu

View the PDF of this article at: https://www.the-jci.org/press/17975.pdf

ACCOMPANYING COMMENTARY:
Tissue glycogen content and glucose intolerance

AUTHOR CONTACT:
Masato Kasuga
Kobe University School of Medicine, Kobe, Japan.
Phone: 81-78-382-5860
Fax: 81-78-382-2084
E-mail: kasuga@med.kobe-u.ac.jp

View the PDF of this commentary at: https://www.the-jci.org/press/18526.pdf


Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A

AUTHOR CONTACT:
Michaela Kuhn
University of Muenster, Muenster, Germany.
Phone : 49-251-83-52597
Fax : 49-251-83-55501
E-mail: mkuhn@uni-muenster.de

View the PDF of this article at: https://www.the-jci.org/press/17061.pdf

ACCOMPANYING COMMENTARY:
A friend within the heart: natriuretic peptide receptor signaling

AUTHOR CONTACT:
Jeffrey Molkentin
Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Phone
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
1-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents, September 15, 2003
6. JCI Table of Contents
7. JCI Table of Contents, 15 August 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI Table Contents May

(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
(Date:7/29/2015)... , ... July 29, 2015 , ... The third Medical ... combination products , in particular, drug/device combinations. The current system received a score ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi ... Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in ... core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... Costello ... new levee system to protect the Orange County, Texas area from future storm ... multi-firm design team in determining several potential levee alignment alternatives for providing protection, Costello ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2
Cached News: